PCMA President Merritt says HHS decision on copay coupons in exchanges will raise costs

An HHS decision that will allow drugmakers' copay and discount coupons to be used by consumers who buy federally subsidized health insurance will raise costs for consumers, says PCMA President and CEO Mark Merritt. "The coupons steer consumers away from lower-cost alternatives to more expensive drugs, increasing costs to insurers and to the government," Merritt said. Lawyer Kevin McAnaney, who specializes in health care fraud and abuse cases, agrees.

View Full Article in:

New York Times (tiered subscription model), The